← Back to Search

Novel Lighting for Fall Prevention in Dementia

N/A

Waitlist Available

Led By Sheryl Zimmerman, PhD

Research Sponsored by University of North Carolina, Chapel Hill

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at study completion (one year)

Awards & highlights

No Placebo-Only Group

Summary

This trial will test lights that outline doorframes to reduce falls in dementia patients in assisted living homes.

Who is the study for?

This trial is for assisted living residents with dementia who try to get out of bed, are not wheelchair-bound, blind, on hospice care, or expected to die/transfer within the study year. They must live alone in a room but can share a bathroom.

What is being tested?

The study tests if special lights around doorframes can reduce nighttime falls in people with dementia. It's a one-year crossover trial where participants experience both the new lighting and regular conditions at different times.

What are the potential side effects?

Since this intervention involves lighting changes rather than medication, side effects may include discomfort from the light or dissatisfaction with the system but no medical side effects are anticipated.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at study completion (one year)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at study completion (one year)

This trial's timeline: 3 weeks for screening, Varies for treatment, and at study completion (one year) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Falls incidence density ratio

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups

Experimental Treatment

Group I: Lighting Sequence 4: LLCCExperimental Treatment2 Interventions

In this arm, the participant will receive the novel lighting condition (L) for the first two quarters (180 days) and then crossover to the control lighting condition (C) for the last two quarters (180 days). Q1 - Novel lighting Q2 - Novel lighting Q3 - Control lighting Q4 - Control lighting

Group II: Lighting Sequence 3: LCCLExperimental Treatment2 Interventions

In this arm, the participant will receive the novel lighting condition (L) for the first quarter (90 days) and then crossover to the control lighting condition (C) for the next two quarters (180 days) and finally crossover again to the novel condition (L) for the last quarter (90 days). Q1 - Novel lighting Q2 - Control lighting Q3 - Control lighting Q4 - Novel lighting

Group III: Lighting Sequence 2: CLLCExperimental Treatment2 Interventions

In this arm, the participant will receive the control lighting condition (C) for the first quarter (90 days) and then crossover to the novel lighting condition (L) for the next two quarters (180 days) and finally crossover again to the control condition (C) for the last quarter (90 days). Q1 - Control lighting Q2 - Novel lighting Q3 - Novel lighting Q4 - Control lighting

Group IV: Lighting Sequence 1: CCLLExperimental Treatment2 Interventions

In this arm, the participant will receive the control lighting condition (C) for the first two quarters (180 days) and then crossover to the novel lighting condition (L) for the last two quarters (180 days). Q1 - Control lighting Q2 - Control lighting Q3 - Novel lighting Q4 - Novel lighting

Do I qualify?Apply below to find out